The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1

Charalampos Moschos, Ioannis Psallidas, Androniki Kollintzu, Sophia Karabula, Andreas Papapetropoulos, Spyros Papiris, Richard W. Light, Charis Roussos, Georgios T. Stathopoulos, Ioannis Kalomenidis

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

PURPOSE: Angiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL DESIGN: MPE was induced by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intraperitoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were killed on day 14. RESULTS: Angiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor foci. The mean ± SEM pleural fluid volumes were 617 ±48 μl and 316 ± 62 μl for the control and treated groups, respectively (P = .001), whereas the mean ± SEM tumor foci were 7.3 ± 1.0 and 3.0 ± 0.52 for the control and treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated with the inhibitor. CONCLUSIONS: Our results indicate that the angiopoietin/Tie2 axis is an important component of MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway could be beneficial for patients with MPE.

Original languageEnglish (US)
Pages (from-to)298-304
Number of pages7
JournalNeoplasia
Volume11
Issue number3
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Angiopoietins
Malignant Pleural Effusion
TIE-2 Receptor
Capillary Permeability
Neoplasms
Pleural Cavity
Control Groups
Cachexia
Tumor Burden
Intraperitoneal Injections
Inbred C57BL Mouse
Vascular Endothelial Growth Factor A
Interleukin-6
Adenocarcinoma
Down-Regulation
Apoptosis
Inflammation
Injections

ASJC Scopus subject areas

  • Cancer Research

Cite this

Moschos, C., Psallidas, I., Kollintzu, A., Karabula, S., Papapetropoulos, A., Papiris, S., ... Kalomenidis, I. (2009). The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1. Neoplasia, 11(3), 298-304. https://doi.org/10.1593/neo.81480

The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1. / Moschos, Charalampos; Psallidas, Ioannis; Kollintzu, Androniki; Karabula, Sophia; Papapetropoulos, Andreas; Papiris, Spyros; Light, Richard W.; Roussos, Charis; Stathopoulos, Georgios T.; Kalomenidis, Ioannis.

In: Neoplasia, Vol. 11, No. 3, 01.01.2009, p. 298-304.

Research output: Contribution to journalArticle

Moschos, C, Psallidas, I, Kollintzu, A, Karabula, S, Papapetropoulos, A, Papiris, S, Light, RW, Roussos, C, Stathopoulos, GT & Kalomenidis, I 2009, 'The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1', Neoplasia, vol. 11, no. 3, pp. 298-304. https://doi.org/10.1593/neo.81480
Moschos C, Psallidas I, Kollintzu A, Karabula S, Papapetropoulos A, Papiris S et al. The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1. Neoplasia. 2009 Jan 1;11(3):298-304. https://doi.org/10.1593/neo.81480
Moschos, Charalampos ; Psallidas, Ioannis ; Kollintzu, Androniki ; Karabula, Sophia ; Papapetropoulos, Andreas ; Papiris, Spyros ; Light, Richard W. ; Roussos, Charis ; Stathopoulos, Georgios T. ; Kalomenidis, Ioannis. / The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1. In: Neoplasia. 2009 ; Vol. 11, No. 3. pp. 298-304.
@article{8a443e97f64e4ccda9513fa517c92315,
title = "The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1",
abstract = "PURPOSE: Angiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL DESIGN: MPE was induced by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intraperitoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were killed on day 14. RESULTS: Angiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor foci. The mean ± SEM pleural fluid volumes were 617 ±48 μl and 316 ± 62 μl for the control and treated groups, respectively (P = .001), whereas the mean ± SEM tumor foci were 7.3 ± 1.0 and 3.0 ± 0.52 for the control and treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated with the inhibitor. CONCLUSIONS: Our results indicate that the angiopoietin/Tie2 axis is an important component of MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway could be beneficial for patients with MPE.",
author = "Charalampos Moschos and Ioannis Psallidas and Androniki Kollintzu and Sophia Karabula and Andreas Papapetropoulos and Spyros Papiris and Light, {Richard W.} and Charis Roussos and Stathopoulos, {Georgios T.} and Ioannis Kalomenidis",
year = "2009",
month = "1",
day = "1",
doi = "10.1593/neo.81480",
language = "English (US)",
volume = "11",
pages = "298--304",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The Angiopoietin/Tie2 axis mediates malignant pleural effusion fonmation 1

AU - Moschos, Charalampos

AU - Psallidas, Ioannis

AU - Kollintzu, Androniki

AU - Karabula, Sophia

AU - Papapetropoulos, Andreas

AU - Papiris, Spyros

AU - Light, Richard W.

AU - Roussos, Charis

AU - Stathopoulos, Georgios T.

AU - Kalomenidis, Ioannis

PY - 2009/1/1

Y1 - 2009/1/1

N2 - PURPOSE: Angiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL DESIGN: MPE was induced by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intraperitoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were killed on day 14. RESULTS: Angiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor foci. The mean ± SEM pleural fluid volumes were 617 ±48 μl and 316 ± 62 μl for the control and treated groups, respectively (P = .001), whereas the mean ± SEM tumor foci were 7.3 ± 1.0 and 3.0 ± 0.52 for the control and treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated with the inhibitor. CONCLUSIONS: Our results indicate that the angiopoietin/Tie2 axis is an important component of MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway could be beneficial for patients with MPE.

AB - PURPOSE: Angiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL DESIGN: MPE was induced by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intraperitoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were killed on day 14. RESULTS: Angiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor foci. The mean ± SEM pleural fluid volumes were 617 ±48 μl and 316 ± 62 μl for the control and treated groups, respectively (P = .001), whereas the mean ± SEM tumor foci were 7.3 ± 1.0 and 3.0 ± 0.52 for the control and treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated with the inhibitor. CONCLUSIONS: Our results indicate that the angiopoietin/Tie2 axis is an important component of MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway could be beneficial for patients with MPE.

UR - http://www.scopus.com/inward/record.url?scp=62549140636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549140636&partnerID=8YFLogxK

U2 - 10.1593/neo.81480

DO - 10.1593/neo.81480

M3 - Article

VL - 11

SP - 298

EP - 304

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 3

ER -